Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte to Report First Quarter Financial Results
08:00am, Thursday, 09'th Apr 2026
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
Incyte Corporation (NASDAQ:INCY) Given Average Rating of “Hold” by Brokerages
02:39am, Wednesday, 08'th Apr 2026
Incyte Corporation (NASDAQ: INCY - Get Free Report) has received an average recommendation of "Hold" from the twenty-one brokerages that are currently covering the stock, MarketBeat reports. One analy
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
04:00pm, Monday, 30'th Mar 2026
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
03:04pm, Saturday, 28'th Mar 2026
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting.
Diversified Trust Co. Has $1.40 Million Position in Incyte Corporation $INCY
04:26am, Thursday, 26'th Mar 2026
Diversified Trust Co. cut its stake in Incyte Corporation (NASDAQ: INCY) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fu
Incyte Announces Executive Leadership Appointments
09:00am, Wednesday, 25'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Executive Leadership Appointments.
Incyte: An Undervalued Healthcare Gem
11:11pm, Sunday, 22'nd Mar 2026
Incyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions. Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong o
Incyte Corporation $INCY Shares Sold by JPMorgan Chase & Co.
05:20am, Sunday, 22'nd Mar 2026
JPMorgan Chase and Co. lessened its stake in Incyte Corporation (NASDAQ: INCY) by 46.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The insti
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
10:00am, Friday, 20'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue
10:24am, Tuesday, 17'th Mar 2026
Incyte is undervalued due to overemphasis on Jakafi's 2028 US patent cliff, despite a diversifying revenue base and robust pipeline. Non-Jakafi segments grew over 50% YoY in 2025, with management guid
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
07:30am, Tuesday, 17'th Mar 2026
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Uni
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Lab
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond
03:55pm, Monday, 16'th Mar 2026
Incyte remains attractively valued, trading at 12.5x 2026 EPS, well below sector medians, with 9% EPS and revenue growth expected. Jakafi, currently 60% of revenue, faces patent expiration in 2028; IN
